On June 30, 2026, Ron Baron (Trades, Portfolio) executed a significant reduction in the firm's position in CareDx Inc (NASDAQ: CDNA), selling 1,399,083 shares at

Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o.

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company's newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally's employment with CareDx. CareDx granted 15,822 shares of common stock restricted stock units (RSUs) to Mr. McNally. The RSU awards were made pursua.

CareDx is helping to improve outcomes for transplant patients. The health monitor's non-invasive tests are in high demand.

CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript

CareDx (CDNA) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.1 per share a year ago.

CareDx NASDAQ: CDNA reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform.

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue of $132 million, an increase of 52% year-over-year Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Services volume of approximately 58,000, an increase of 17% year-o.

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.